Surface Oncology to Participate in the Baird 2022 Global Healthcare Conference
Surface Oncology (Nasdaq: SURF) will have its CEO, Rob Ross, participate in a fireside chat at the Baird 2022 Global Healthcare Conference on September 14, 2022, at 10:15 a.m. ET. This event will provide insights into the company’s development of next-generation immunotherapies targeting the tumor microenvironment. Interested attendees can access a live webcast on Surface Oncology’s Investor Relations page, with a replay available afterward. The company is advancing several clinical-stage programs and collaborations aimed at enhancing cancer treatment.
- None.
- None.
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 10:15 a.m. ET.
A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Surface Oncology website at https://investors.surfaceoncology.com/. In addition, a replay of the webcast will be available on the company’s website following the presentation.
About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on selectively depleting regulatory T cells in the tumor microenvironment via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Contact
Scott Young
(617) 865-3250
syoung@surfaceoncology.com
FAQ
When is Surface Oncology's CEO participating in the Baird 2022 Global Healthcare Conference?
How can I watch the presentation by Surface Oncology at the healthcare conference?
What are the main focuses of Surface Oncology's research?
Does Surface Oncology have any partnerships with other pharmaceutical companies?
Where can I find more information about Surface Oncology?
